Does SLT combined with NIBS enhance naming recovery in post-stroke aphasia? A meta-analysis and systematic review.
Linsong Chai, Yunshi Huang, Xinqi Guo and 3 others
PMID 38875053WHAT IT FOUND
NIBS added to speech therapy improved naming in post-stroke aphasia patients. rTMS showed a clear benefit; tDCS did not.
At follow-up, rTMS kept a real advantage while tDCS faded to a very small, unclear effect.
Key findings
01Across 18 randomised trials, adding NIBS to speech therapy produced a small but significant improvement in naming compared with sham stimulation plus the same therapy (SMD 0.25, 95% CI 0.06 to 0.44, p = 0.009).
02rTMS combined with SLT showed a significant benefit on naming (SMD 0.25, p = 0.03), while tDCS combined with SLT showed a similar point estimate but did not reach significance (SMD 0.26, p = 0.12). The difference between the two techniques was not significant (p = 0.98).
03At follow-up, NIBS plus SLT maintained a moderate advantage over SLT alone (SMD 0.43, p = 0.006). rTMS kept a significant medium effect (SMD 0.53, p = 0.003) while tDCS dropped to a very small, non-significant effect (SMD 0.13, p = 0.67).
STILL TO COME
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Most individual trials were small (10 to 30 patients); only one met the recommended minimum of 20 per group. Stimulation parameters, speech therapy content, and follow-up timing varied widely across studies, making it hard to isolate what exactly produced the benefit. Only English-language publications were included and unpublished work was excluded, both of which can skew results toward positive findings. Only 7 of the 18 studies reported follow-up data, so the long-term picture rests on a thin base. The chronic aphasia subgroup had just 5 studies, so the finding of no significant benefit in that group is underpowered. 7 of the 18 studies did not describe how they randomised patients.
The easy way to misread this
Do not read the overall positive result as evidence that tDCS works. The tDCS subgroup did not reach significance at either time point (p = 0.12 post-intervention, p = 0.67 at follow-up), and only 3 of the 7 follow-up studies used tDCS.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →